AP2002002554A0 - Ox (ADI) azolyl-hydroxamic acids useful as procollagen C- proteinase inhibitors. - Google Patents

Ox (ADI) azolyl-hydroxamic acids useful as procollagen C- proteinase inhibitors.

Info

Publication number
AP2002002554A0
AP2002002554A0 APAP/P/2002/002554A AP2002002554A AP2002002554A0 AP 2002002554 A0 AP2002002554 A0 AP 2002002554A0 AP 2002002554 A AP2002002554 A AP 2002002554A AP 2002002554 A0 AP2002002554 A0 AP 2002002554A0
Authority
AP
ARIPO
Prior art keywords
procollagen
azolyl
adi
acids useful
hydroxamic acids
Prior art date
Application number
APAP/P/2002/002554A
Other languages
English (en)
Inventor
Simon Bailey
Stephane Billotte
Andrew Michael Derrick
Paul Vincent Fish
Kim James
Nicholas Murray Thomson
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AP2002002554A0 publication Critical patent/AP2002002554A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/48—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a saturated carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/12—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. N-hydroxyamidines
    • C07C259/14—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. N-hydroxyamidines having carbon atoms of hydroxamidine groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/022—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2
    • C07K5/0222—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2 with the first amino acid being heterocyclic, e.g. Pro, Trp
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
APAP/P/2002/002554A 1999-12-23 2000-12-12 Ox (ADI) azolyl-hydroxamic acids useful as procollagen C- proteinase inhibitors. AP2002002554A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9930570.8A GB9930570D0 (en) 1999-12-23 1999-12-23 Therapy
PCT/IB2000/001855 WO2001047901A1 (fr) 1999-12-23 2000-12-12 Acides ox(adi)azolyl-hydroxamiques utilises comme inhibiteurs de la procollagene c-proteinase

Publications (1)

Publication Number Publication Date
AP2002002554A0 true AP2002002554A0 (en) 2002-06-30

Family

ID=10866986

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/2002/002554A AP2002002554A0 (en) 1999-12-23 2000-12-12 Ox (ADI) azolyl-hydroxamic acids useful as procollagen C- proteinase inhibitors.

Country Status (32)

Country Link
EP (1) EP1240152B1 (fr)
JP (1) JP2003519133A (fr)
KR (1) KR20020067570A (fr)
CN (1) CN1423638A (fr)
AP (1) AP2002002554A0 (fr)
AR (1) AR031085A1 (fr)
AT (1) ATE284393T1 (fr)
AU (1) AU1875601A (fr)
BG (1) BG106866A (fr)
BR (1) BR0016717A (fr)
CA (1) CA2395186C (fr)
CO (1) CO5261622A1 (fr)
DE (1) DE60016629T2 (fr)
EA (1) EA200200596A1 (fr)
EE (1) EE200200358A (fr)
ES (1) ES2231292T3 (fr)
GB (1) GB9930570D0 (fr)
GT (1) GT200000221A (fr)
HU (1) HUP0204585A3 (fr)
IL (1) IL149372A0 (fr)
IS (1) IS6363A (fr)
MA (1) MA26858A1 (fr)
MX (1) MXPA02006315A (fr)
NO (1) NO20023058L (fr)
OA (1) OA12125A (fr)
PA (1) PA8508301A1 (fr)
PE (1) PE20010951A1 (fr)
PL (1) PL357512A1 (fr)
SK (1) SK8102002A3 (fr)
TN (1) TNSN00250A1 (fr)
TR (1) TR200201642T2 (fr)
WO (1) WO2001047901A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0025310D0 (en) * 2000-10-16 2000-11-29 Pfizer Ltd Process
US6452041B1 (en) 2000-10-16 2002-09-17 Pfizer Inc. Olefination process to itaconate and succinate derivatives
US6716861B2 (en) 2000-12-21 2004-04-06 Pfizer, Inc. 3-ox(adi)azolylpropanohydroxamic acids useful as procollagen C-proteinase inhibitors
GB0031321D0 (en) * 2000-12-21 2001-02-07 Pfizer Ltd Treatment
GB0108102D0 (en) * 2001-03-30 2001-05-23 Pfizer Ltd Compounds
US6645993B2 (en) 2001-03-30 2003-11-11 Warner-Lambert Company 3-heterocyclylpropanohydroxamic acid PCP inhibitors
GB0108097D0 (en) * 2001-03-30 2001-05-23 Pfizer Ltd Compounds
US6821972B2 (en) 2001-03-30 2004-11-23 Pfizer Inc. 3-heterocyclylpropanohydroxamic acid PCP inhibitors
GB0202254D0 (en) * 2002-01-31 2002-03-20 Pfizer Ltd Prevention of scarring
GB0204159D0 (en) * 2002-02-22 2002-04-10 British Biotech Pharm Metalloproteinase inhibitors
US8133903B2 (en) 2003-10-21 2012-03-13 Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center Methods of use of inhibitors of phosphodiesterases and modulators of nitric oxide, reactive oxygen species, and metalloproteinases in the treatment of peyronie's disease, arteriosclerosis and other fibrotic diseases
OA13050A (en) 2003-04-29 2006-11-10 Pfizer Ltd 5,7-diaminopyrazolo [4,3-D] pyrimidines useful in the treatment of hypertension.
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
ATE417849T1 (de) 2004-04-07 2009-01-15 Pfizer Pyrazoloä4,3-düpyrimidine
WO2009097893A1 (fr) * 2008-02-04 2009-08-13 Proyecto De Biomedicina Cima, S.L. Procédés de traitement d'une maladie cardiaque associée à une fibrose myocardique à l'aide d'un inhibiteur de pcp
CA2936467A1 (fr) 2014-01-10 2015-07-16 Glaxosmithkline Intellectual Property (No.2) Limited Derives d'hydroxy formamide et leur utilisation
CN108530378B (zh) * 2018-05-29 2021-09-14 济南大学 一类含有噁二唑结构的氮原子双取代异羟肟酸类化合物、用途及其制备方法
CN108721282B (zh) * 2018-07-13 2022-02-15 南京市儿童医院 Uk383367在制备用于减轻肾纤维化相关病症的药物中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997031892A1 (fr) * 1996-03-01 1997-09-04 Sankyo Company, Limited Derives d'acide hydroxamique
CN1299282A (zh) * 1998-03-10 2001-06-13 史密丝克莱恩比彻姆公司 玻连蛋白受体拮抗剂

Also Published As

Publication number Publication date
TNSN00250A1 (fr) 2002-05-30
EE200200358A (et) 2003-10-15
PA8508301A1 (es) 2002-08-26
GB9930570D0 (en) 2000-02-16
CA2395186C (fr) 2006-03-28
IS6363A (is) 2002-04-26
CO5261622A1 (es) 2003-03-31
CN1423638A (zh) 2003-06-11
ATE284393T1 (de) 2004-12-15
CA2395186A1 (fr) 2001-07-05
JP2003519133A (ja) 2003-06-17
NO20023058D0 (no) 2002-06-24
EP1240152B1 (fr) 2004-12-08
DE60016629T2 (de) 2005-12-08
SK8102002A3 (en) 2003-09-11
BR0016717A (pt) 2002-09-03
AU1875601A (en) 2001-07-09
GT200000221A (es) 2002-06-14
EA200200596A1 (ru) 2002-12-26
HUP0204585A3 (en) 2006-01-30
TR200201642T2 (tr) 2002-11-21
PE20010951A1 (es) 2001-09-24
DE60016629D1 (de) 2005-01-13
EP1240152A1 (fr) 2002-09-18
AR031085A1 (es) 2003-09-10
WO2001047901A1 (fr) 2001-07-05
MA26858A1 (fr) 2004-12-20
PL357512A1 (en) 2004-07-26
BG106866A (bg) 2003-03-31
IL149372A0 (en) 2002-11-10
OA12125A (en) 2006-05-05
HUP0204585A2 (hu) 2003-04-28
ES2231292T3 (es) 2005-05-16
NO20023058L (no) 2002-08-23
KR20020067570A (ko) 2002-08-22
MXPA02006315A (es) 2002-11-29

Similar Documents

Publication Publication Date Title
AP2002002554A0 (en) Ox (ADI) azolyl-hydroxamic acids useful as procollagen C- proteinase inhibitors.
MXPA05001354A (es) Piperidina-ftalazonas sustituidas por pirrolidinodiona como inhibidores pde4.
GB9919776D0 (en) Compoujnds
DK0931788T3 (da) Metalloproteasehæmmere
MXPA02011977A (es) Herbicidas de piridina sustituidas.
TW200504061A (en) Pyrazolopyridine derivatives
EA200000826A1 (ru) Галоидированные производные амидиноаминокислот, применимые в качестве ингибиторов no-синтазы
EA200200510A1 (ru) 4-карбоксиамино-2-этил-1,2,3,4-тетрагидрохинолин в кристаллической форме как ингибитор сетр
AP2002002466A0 (en) 3-heterocycliylpropanohydroxamic acid PCP INHIBITORS.
TR200201128T2 (tr) PDE4 inhibitörleri olarak tetrahidrotiyopiranfitalazinon türevleri.
EE200300008A (et) COMT-i inhibeeriva aktiivsusega kumariini derivaadid
EA200000628A1 (ru) Ингибиторы металлопротеаз матрикса
MXPA06003345A (es) Derivados de aminopiridina como inhibidores de la no-sintasa inducible.
ATE374189T1 (de) Phthalazinon-derivate als pde 4 hemmer
AP2001002045A0 (en) FKBP inhibitors.
MXPA05006957A (es) Nuevos derivados de fosforamida.
AP2002002464A0 (en) 3- Heterocyclyl propanohydroxamic acid PCP inhibitors.
ES2159489A1 (es) Nuevos derivados de imidazol con actividad antiinflamatoria.
BG105965A (en) C10 ester substituted taxanes and their application as antitumor agents
PT1104419E (pt) Derivados de azabicicloheptano substituidos no azoto sua preparacao e utilizacao
ES2166710A1 (es) Nuevos compuestos heterociclicos con actividad antiinflamatoria.
ATE238781T1 (de) Verwendung von katecholderivaten als proteinaseinhibitoren
IL169334A0 (en) Phthalazine derivatives as phosphodiesterase 4 inhibitors
AP2001002047A0 (en) Isoquinoliness as urokinase inhibitors.
AU2000246281A1 (en) Piperidine compounds and process for providing such